The most important and earliest cluster to emerge was #0 (probiotics), which developed 4 clusters, including #1 (nonalcoholic steatohepatitis), #2 (nonalcoholic fatty liver disease), #3 (MAFLD), #8 (docosahexaenoic acid), the clustering that immediately follows were #1 (nonalcoholic steatohepatitis), #2 (nonalcoholic fatty liver disease), the more contemporary research clustering were #19 (lysosomal acid lipase deficiency), #20 (immune checkpoint inhibitor), #21 (peroxisome proliferator-activated receptor-gamma). Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.